Evidence map›Paper›PMID 27593557›Full record

ArticleEpigenetics2016

Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.

Benjamin Goeppert, Christina Ernst, Constance Baer, Stephanie Roessler, Marcus Renner, Arianeb Mehrabi, Mohammadreza Hafezi, Anita Pathil, Arne Warth, Albrecht Stenzinger and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Epigenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Wnt/β-Catenin Signaling in Liver Pathobiology.Annual review of pathology · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Cholangiocarcinoma and liver transplantation: What we know so far?World journal of gastrointestinal pathophysiology · 2021
    Review
  12. Article
  13. Current challenges to underpinning the genetic basis for cholangiocarcinoma.Expert review of gastroenterology & hepatology · 2021
    Review
  14. Exosomal noncoding RNAs in cholangiocarcinoma: Laboratory noise or hope?World journal of gastrointestinal surgery · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Benjamin Goepperta Institute of Pathology, University Hospital Heidelberg , Germany.
Christina Ernstb Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Constance Baerb Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Stephanie Roesslera Institute of Pathology, University Hospital Heidelberg , Germany.
Marcus Rennera Institute of Pathology, University Hospital Heidelberg , Germany.
Arianeb Mehrabic Department of General , Visceral, and Transplantation Surgery, University Hospital Heidelberg , Germany.
Mohammadreza Hafezic Department of General , Visceral, and Transplantation Surgery, University Hospital Heidelberg , Germany.
Anita Pathild Department of Internal Medicine IV, Gastroenterology and Hepatology , University Hospital Heidelberg , Germany.
Arne Wartha Institute of Pathology, University Hospital Heidelberg , Germany.
Albrecht Stenzingera Institute of Pathology, University Hospital Heidelberg , Germany.
Wilko Weicherte Technical University of Munich, University Hospital, Institute for General Pathology and Pathological Anatomy , Germany.
Marion Bährb Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Rainer Willf Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Peter Schirmachera Institute of Pathology, University Hospital Heidelberg , Germany.
Christoph Plassb Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Dieter Weichenhanb Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
University Hospital Heidelberg · DEGerman Cancer Research Center · DEHeidelberg University · DEEpigenomics (Germany) · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CC) is a rare malignancy of the extrahepatic or intrahepatic biliary tract with an outstanding poor prognosis. Non-surgical therapeutic regimens result in minimally improved survival of CC patients. Global genomic analyses identified a few recurrently mutated genes, some of them in genes involved in epigenetic patterning. In a previous study, we demonstrated global DNA methylation changes in CC, indicating major contribution of epigenetic alterations to cholangiocarcinogenesis. Here, we aimed at the identification and characterization of CC-related, differentially methylated regions (DMRs) in potential microRNA promoters and of genes targeted by identified microRNAs. Twenty-seven hypermethylated and 13 hypomethylated potential promoter regions of microRNAs, known to be associated with cancer-related pathways like Wnt, ErbB, and PI3K-Akt signaling, were identified. Selected DMRs were confirmed in 2 independent patient cohorts. Inverse correlation between promoter methylation and expression suggested miR-129-2 and members of the miR-200 family (miR-200a, miR-200b, and miR-429) as novel tumor suppressors and oncomiRs, respectively, in CC. Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7), and cadherin-6 (CDH6) were identified as presumed targets in CC. Tissue microarrays of a representative and well-characterized cohort of biliary tract cancers (n=212) displayed stepwise downregulation of CDH6 and association with poor patient outcome. Ectopic expression of CDH6 on the other hand, delayed growth in the CC cell lines EGI-1 and TFK-1, together suggesting a tumor suppressive function of CDH6. Our work represents a valuable repository for the study of epigenetically altered miRNAs in cholangiocarcinogenesis and novel putative, CC-related tumor suppressive miRNAs and oncomiRs.

Indexed as

AdultAgedAged, 80 and overCadherinsCell Cycle ProteinsCell Line, TumorCholangiocarcinomaDNA MethylationEpigenesis, GeneticF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FemaleGene Expression Regulation, NeoplasticGTPase-Activating ProteinsHumansMaleCadherinsCell Cycle ProteinsDLC1 protein, humanF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanGTPase-Activating ProteinsK cadherinMicroRNAsMIRN429 microRNA, humanTumor Suppressor ProteinsUbiquitin-Protein LigasesBiliary tract cancerDNA methylationepigenomicsmicroRNApatient survival

Identifiers

PMID27593557
PMCPMC5221660
OpenAlexW2517498579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.